elranatamab will raise the level or influence of fentanyl transdermal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Elranatamab causes cytokine release syndrome (CRS) which will suppress exercise of CYP enzymes, resulting in enhanced exposure of CYP substrates.eluxadoline increases levels of fentanyl transdermal by af